CureDuchenne, as an early investor in Avidity Biosciences, is excited to share the announcement of the Phase 1/2 EXPLORE44™ clinical trial of AOC 1044 in healthy volunteers and participants with […]
Leading Global Nonprofit Expands Professional Training Program to Meet Specialized Needs of Individuals with the Neuromuscular Disease NEWPORT BEACH, Calif., (October 10, 2022) – CureDuchenne, a global leader in research, […]
Southern California’s Premier Wine Event Brings Together Acclaimed Napa Valley Vintners Under One Roof to Raise Funds for CureDuchenne NEWPORT BEACH Calif., September 29, 2022 – CureDuchenne and Vintner Chair Dana Estates will host […]
Palm Springs-themed Event Supports Global Nonprofit Focused on Finding and Funding a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (September 23, 2022) – CureDuchenne, a leading global nonprofit focused […]
At the core of the MAA submission are positive data from the pivotal Phase 2b VISION-DMD study which comprised a (1) 24-week period to demonstrate efficacy and safety of vamorolone […]
09/29/22 8:30 AM EDT CAMBRIDGE, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has […]
Participants currently enrolled in MARINA and MARINA-OLE™ trials may continue to be treated with AOC 1001 Avidity received Investigational New Drug (IND) clearance for FSHD and DMD studies from FDA; programs […]
NHL All-Star Ryan Getzlaf Joins Forces with Global Nonprofit to Help Find a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (September 20, 2022) – CureDuchenne, a leading global nonprofit […]
Dr. Paolo Bettica will review recently completed study analysis for the Italfarmaco Phase 3 randomized controlled trial of givinostat in boys with Duchenne muscular dystrophy (DMD). He will answer your […]
